Navigation Links
Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimer's Disease Patients

NEW YORK, April 24, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and BrightFocus Foundation today announced a funding collaboration that will support a Phase I human clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer's disease. Through this partnership, the organizations are working to address a gap in funding that exists for these types of early stage studies. The trial will be conducted by ReXceptor Inc., a biotechnology company set-up by researchers at Case Western Reserve University (CWRU), and will examine the efficacy of bexarotene on key Alzheimer's disease indicators, including brain amyloid beta and apolipoprotein E (apoE).

"This clinical trial will evaluate if bexarotene can affect critical biomarkers in the human brain, a key step in the quest to develop effective and safe treatments for Alzheimer's patients," said Howard Fillit , MD, executive director and chief scientific officer of the Alzheimer's Drug Discovery Foundation. "We are grateful to BrightFocus Foundation for partnering with us to fund this important study."

Bexarotene has been commercially available in the US for more than a decade as an orally administered treatment for T-cell lymphoma. Recently, Gary Landreth , PhD, the Riuko and Archie G. Co Professor of Neurosciences and Director of the Alzheimer's Research Laboratory at CWRU's School of Medicine, along with other researchers, demonstrated that bexarotene might also be useful in the treatment of Alzheimer's disease. Landreth's group showed that bexarotene increased brain apoE protein levels and cleared amyloid from the brain (a key target for Alzheimer's disease) of mice genetically engineered to exhibit some of the characteristics of Alzheimer's disease, which resulted in improved memory and cognition. To further advance bexarotene and related compounds through drug development, Dr. Landreth co-founded the biotechnology company ReXceptor in 2011.

"Funding for pilot clinical trials is in short supply," said Stacy Pagos Haller , the president and chief executive officer of BrightFocus Foundation. "Partnering with another foundation in the community that shares a common goal makes research like this possible. In this time of shrinking corporate and pharmaceutical budgets, this project -- from animal model to clinical trial -- would not happen without the catalytic support of our organizations. The effort to cure Alzheimer's disease needs many voices. This project demonstrates what can be achieved when a mission of one organization becomes a movement of many."

Partial funding for ReXceptor Inc.'s trial includes The Charles Evans Foundation/Alzheimer's Drug Discovery Award to ReXceptor Therapeutics of $500,000 and a $250,000 contribution from BrightFocus to the collaboration with ADDF. Additional funds are originating from other sources of translational support, including a $200,000 investment from CWRU, to enable conduct of the full Phase I study.

The Phase I trial, set to commence later this year, will evaluate at least 12 healthy human subjects. This study will be conducted by C2N Diagnostics and Compass Research, Inc. and will employ proprietary technology allowing the measurement of apoE and amyloid beta related biomarkers in the spinal fluid of individuals following treatment with bexarotene.

About the Alzheimer's Drug Discovery Foundation (ADDF)
The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has invested nearly $60 million to fund 400 Alzheimer's drug discovery programs and
clinical trials in academic centers and biotechnology companies in 18 countries. For more information, please visit 

About BrightFocus Foundation
BrightFocus Foundation (formerly known as American Health Assistance Foundation) is a nonprofit organization supporting research and providing public education to help eradicate brain and eye diseases, including Alzheimer's disease, macular degeneration, and glaucoma. We are working to save mind and sight. BrightFocus has provided $130 million in grants worldwide. For more information, please visit

About ReXceptor Inc.
ReXceptor Inc. is focused on the development of disease modifying, small molecule therapeutics for the treatment of Alzheimer's disease and other neurological disorders.  The Cleveland, Ohio company was founded in 2011 based on work emanating from the laboratory of co-founder, Dr. Gary Landreth of Case Western Reserve University. For more information, please visit

SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobasĀ® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):